Latest news with #HimsAndHersHealth
Globe and Mail
02-07-2025
- Business
- Globe and Mail
The Week In AI: Scaling Wars and Alignment Landmines
Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report
Yahoo
07-06-2025
- Business
- Yahoo
Is Hims & Hers Health a Smart Buy Right Now?
Hims & Hers is the newest darling disrupting the telemedicine space. While shares have jumped 157% over the last year, Wall Street analysts don't seem overly bullish on the stock. Despite impressive results in the business, Hims & Hers has a high short interest -- making a short-squeeze a possibility. 10 stocks we like better than Hims & Hers Health › When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Technologies or CoreWeave remain red-hot in a strong technology sector. But smart investors understand that there are myriad opportunities beyond the usual suspects in tech. One company that has emerged as a new favorite among investors is telemedicine business Hims & Hers Health (NYSE: HIMS). With shares up 157% over the last 12 months as of market close June 4, Hims & Hers Health looks like the next monster growth stock at the intersection of healthcare and technology. Let's assess the state of Hims & Hers' business and then take a look at what Wall Street thinks. Is buying shares of this telemedicine darling a good idea right now? Read on to find out. Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss. At the core of the company's business model is a subscription platform. At the end of the first quarter, Hims & Hers boasted 2.4 million subscribers, which represented an increase of 38% year over year. This translated into revenue of $586 million for the quarter, up by a jaw-dropping 111% year over year. By keeping its business primarily online, Hims & Hers can benefit in a couple of ways. First, subscription revenue is recurring and therefore carries high gross margins. Second, by keeping its user base using its offerings, the company has the flexibility to spend less on marketing and invest in other areas, such as technology or research and development, in an effort to bolster customer acquisition strategies. Per management's vision, Hims & Hers is doubling down on investments in AI to get a better sense of its customer data. This could be a savvy move, as it may help the company unlock new expansion opportunities. While the ideas above paint a picture of a fast-growing, disruptive new solution in the healthcare space, Wall Street doesn't seem totally sold on Hims & Hers just yet. Over the last month, a number of equity research analysts, including Piper Sandler, Citigroup, Bank of America, and Morgan Stanley, have each maintained ratings of neutral, sell, underperform, or equal-weight. Another way of looking at this is that among some of the largest banks on Wall Street, none seem to have a compelling buy rating on Hims & Hers stock. In addition, the average price estimate among analysts for Hims & Hers stock is roughly $48, implying 12% downside from trading levels as of June 4. Given Wall Street's somewhat bearish sentiment, what could be fueling the stock's seemingly unstoppable rally? I think the company's high short interest could be the cause of the rise in its stock. Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only is Hims & Hers' short interest much higher than the usual benchmarks, it's also rising. A high short interest can fuel volatility and even a rise in a stock's price if investors who are shorting a stock need to buy shares in the company to return the borrowed shares and close out their position. This is known as short covering, and it often leads to pronounced increases in a stock for a fleeting period of time, adding to volatility. You might be more familiar with these dynamics as a short squeeze. Despite notable subscriber growth and expanding markets, Hims & Hers stock exhibits too much volatility for my liking, and with that, comes a high degree of uncertainty. At first glance, I can understand what makes Hims & Hers look like an appealing investment. Telemedicine represents a compelling opportunity at the intersection of healthcare and technology, and Hims & Hers has certainly proven that it can consistently acquire users and monetize them. Moreover, the prospects that AI presents in the healthcare space more broadly shouldn't be discounted -- further validating the vision management has for Hims & Hers' long-term growth. Nevertheless, I struggle to look past the meme stock type of behavior exhibited here. While some investors have certainly made money owning this stock, I am suspicious if their profits were sparked by the right reasons. Said differently, I view Hims & Hers as more of a swing trading stock (timing is everything) as opposed to a sound long-term opportunity at this time. For these reasons, I would pass on Hims & Hers at the moment. While I'm intrigued by the company's potential, I think shares have run up considerably and would not be surprised to see some contraction in the share price sooner than later. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Bank of America is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Adam Spatacco has positions in Palantir Technologies. The Motley Fool has positions in and recommends Bank of America, CrowdStrike, Hims & Hers Health, and Palantir Technologies. The Motley Fool has a disclosure policy. Is Hims & Hers Health a Smart Buy Right Now? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
3 Stocks Estimated To Be Undervalued By Up To 19.5% Offering Investment Opportunities
Over the last 7 days, the United States market has experienced a slight decline of 1.4%, yet it has shown resilience with an 11% rise over the past year, and earnings are projected to grow by 14% annually. In this environment, identifying stocks that are estimated to be undervalued can present compelling investment opportunities for those looking to capitalize on potential market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Berkshire Hills Bancorp (NYSE:BHLB) $25.09 $50.02 49.8% UMH Properties (NYSE:UMH) $16.38 $32.38 49.4% Super Group (SGHC) (NYSE:SGHC) $8.37 $16.54 49.4% Burke & Herbert Financial Services (NasdaqCM:BHRB) $55.59 $108.72 48.9% Advanced Flower Capital (NasdaqGM:AFCG) $4.83 $9.39 48.6% Hims & Hers Health (NYSE:HIMS) $53.52 $106.29 49.6% Finward Bancorp (NasdaqCM:FNWD) $30.00 $59.39 49.5% TXO Partners (NYSE:TXO) $15.30 $29.97 49% ZEEKR Intelligent Technology Holding (NYSE:ZK) $29.40 $57.19 48.6% Agora (NasdaqGS:API) $3.68 $7.25 49.2% Click here to see the full list of 169 stocks from our Undervalued US Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: Futu Holdings Limited operates as a digitalized securities brokerage and wealth management product distributor in Hong Kong and internationally, with a market cap of approximately $15.20 billion. Operations: The company's revenue primarily comes from its online brokerage services and margin financing services, generating approximately HK$11.97 billion. Estimated Discount To Fair Value: 19.5% Futu Holdings is trading at US$111.44, below its estimated fair value of US$138.4, indicating it may be undervalued based on cash flows. Analysts expect earnings to grow by 19.1% annually, outpacing the broader U.S. market's 14.3%. Recent financials show robust growth with annual revenue reaching HKD 13.59 billion and net income at HKD 5.44 billion for 2024, highlighting strong operational performance despite no recent share buybacks being executed as planned. Our expertly prepared growth report on Futu Holdings implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Futu Holdings. Overview: Inter & Co, Inc., with a market cap of $3.06 billion, operates through its subsidiaries in banking and spending, investments, and insurance brokerage businesses. Operations: The company's revenue is primarily derived from its banking and spending segment, which generated R$4.10 billion, followed by investments at R$261.13 million and insurance brokerage at R$196.98 million. Estimated Discount To Fair Value: 15.8% Inter & Co's recent earnings report shows net interest income of BRL 1.36 billion, up from BRL 992.42 million a year ago, with net income rising to BRL 286.59 million. Trading at US$7.11, below its estimated fair value of US$8.44, it appears undervalued based on cash flows despite a high bad loans ratio of 9.3%. Earnings and revenue are expected to grow significantly faster than the market over the next three years. Our growth report here indicates Inter & Co may be poised for an improving outlook. Get an in-depth perspective on Inter & Co's balance sheet by reading our health report here. Overview: Corning Incorporated operates in the optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and internationally, with a market cap of approximately $41.26 billion. Operations: Corning's revenue segments include Optical Communications at $5.08 billion, Display Technologies at $3.91 billion, Specialty Materials at $2.07 billion, Life Sciences at $977 million, and Hemlock and Emerging Growth Businesses at $1.25 billion. Estimated Discount To Fair Value: 12.3% Corning is trading at US$48.55, below its estimated fair value of US$55.37, suggesting it may be undervalued based on cash flows. Despite a lower net profit margin this year and significant insider selling recently, earnings are expected to grow 27.1% annually over the next three years, outpacing the US market's growth rate. Recent collaborations in AI and mobile technology with Broadcom and Samsung could bolster future revenue streams amidst high debt levels. Insights from our recent growth report point to a promising forecast for Corning's business outlook. Take a closer look at Corning's balance sheet health here in our report. Reveal the 169 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:FUTU NasdaqGS:INTR and NYSE:GLW. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
3 Stocks Estimated To Be Undervalued By Up To 19.5% Offering Investment Opportunities
Over the last 7 days, the United States market has experienced a slight decline of 1.4%, yet it has shown resilience with an 11% rise over the past year, and earnings are projected to grow by 14% annually. In this environment, identifying stocks that are estimated to be undervalued can present compelling investment opportunities for those looking to capitalize on potential market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Berkshire Hills Bancorp (NYSE:BHLB) $25.09 $50.02 49.8% UMH Properties (NYSE:UMH) $16.38 $32.38 49.4% Super Group (SGHC) (NYSE:SGHC) $8.37 $16.54 49.4% Burke & Herbert Financial Services (NasdaqCM:BHRB) $55.59 $108.72 48.9% Advanced Flower Capital (NasdaqGM:AFCG) $4.83 $9.39 48.6% Hims & Hers Health (NYSE:HIMS) $53.52 $106.29 49.6% Finward Bancorp (NasdaqCM:FNWD) $30.00 $59.39 49.5% TXO Partners (NYSE:TXO) $15.30 $29.97 49% ZEEKR Intelligent Technology Holding (NYSE:ZK) $29.40 $57.19 48.6% Agora (NasdaqGS:API) $3.68 $7.25 49.2% Click here to see the full list of 169 stocks from our Undervalued US Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: Futu Holdings Limited operates as a digitalized securities brokerage and wealth management product distributor in Hong Kong and internationally, with a market cap of approximately $15.20 billion. Operations: The company's revenue primarily comes from its online brokerage services and margin financing services, generating approximately HK$11.97 billion. Estimated Discount To Fair Value: 19.5% Futu Holdings is trading at US$111.44, below its estimated fair value of US$138.4, indicating it may be undervalued based on cash flows. Analysts expect earnings to grow by 19.1% annually, outpacing the broader U.S. market's 14.3%. Recent financials show robust growth with annual revenue reaching HKD 13.59 billion and net income at HKD 5.44 billion for 2024, highlighting strong operational performance despite no recent share buybacks being executed as planned. Our expertly prepared growth report on Futu Holdings implies its future financial outlook may be stronger than recent results. Click here and access our complete balance sheet health report to understand the dynamics of Futu Holdings. Overview: Inter & Co, Inc., with a market cap of $3.06 billion, operates through its subsidiaries in banking and spending, investments, and insurance brokerage businesses. Operations: The company's revenue is primarily derived from its banking and spending segment, which generated R$4.10 billion, followed by investments at R$261.13 million and insurance brokerage at R$196.98 million. Estimated Discount To Fair Value: 15.8% Inter & Co's recent earnings report shows net interest income of BRL 1.36 billion, up from BRL 992.42 million a year ago, with net income rising to BRL 286.59 million. Trading at US$7.11, below its estimated fair value of US$8.44, it appears undervalued based on cash flows despite a high bad loans ratio of 9.3%. Earnings and revenue are expected to grow significantly faster than the market over the next three years. Our growth report here indicates Inter & Co may be poised for an improving outlook. Get an in-depth perspective on Inter & Co's balance sheet by reading our health report here. Overview: Corning Incorporated operates in the optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and internationally, with a market cap of approximately $41.26 billion. Operations: Corning's revenue segments include Optical Communications at $5.08 billion, Display Technologies at $3.91 billion, Specialty Materials at $2.07 billion, Life Sciences at $977 million, and Hemlock and Emerging Growth Businesses at $1.25 billion. Estimated Discount To Fair Value: 12.3% Corning is trading at US$48.55, below its estimated fair value of US$55.37, suggesting it may be undervalued based on cash flows. Despite a lower net profit margin this year and significant insider selling recently, earnings are expected to grow 27.1% annually over the next three years, outpacing the US market's growth rate. Recent collaborations in AI and mobile technology with Broadcom and Samsung could bolster future revenue streams amidst high debt levels. Insights from our recent growth report point to a promising forecast for Corning's business outlook. Take a closer look at Corning's balance sheet health here in our report. Reveal the 169 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:FUTU NasdaqGS:INTR and NYSE:GLW. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
